Carl Dambkowski Sells 5,500 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $78.71, for a total value of $432,905.00. Following the completion of the transaction, the insider directly owned 205,648 shares of the company’s stock, valued at approximately $16,186,554.08. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, May 6th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $84.14, for a total value of $462,770.00.
• On Wednesday, April 1st, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $84.84, for a total value of $466,620.00.

Apogee Therapeutics Trading Down 4.4%

Apogee Therapeutics stock opened at $86.92 on Friday. Apogee Therapeutics Inc. has a 12 month low of $34.34 and a 12 month high of $95.32. The business’s 50 day simple moving average is $83.96 and its 200 day simple moving average is $76.58. The company has a market cap of $5.38 billion, a price-to-earnings ratio of -20.07 and a beta of 0.62.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, May 11th. The company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.01. As a group, equities research analysts forecast that Apogee Therapeutics Inc. will post -4.45 earnings per share for the current fiscal year.

Institutional Trading of Apogee Therapeutics

A number of institutional investors have recently modified their holdings of APGE. Commonwealth Equity Services LLC lifted its holdings in Apogee Therapeutics by 2.2% in the fourth quarter. Commonwealth Equity Services LLC now owns 7,151 shares of the company’s stock worth $540,000 after buying an additional 152 shares during the period. Seven Fleet Capital Management LP lifted its holdings in Apogee Therapeutics by 9.4% in the first quarter. Seven Fleet Capital Management LP now owns 1,969 shares of the company’s stock worth $166,000 after buying an additional 169 shares during the period. Stifel Financial Corp lifted its holdings in Apogee Therapeutics by 3.5% in the fourth quarter. Stifel Financial Corp now owns 5,214 shares of the company’s stock worth $394,000 after buying an additional 175 shares during the period. ANTIPODES PARTNERS Ltd lifted its holdings in Apogee Therapeutics by 41.2% in the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after buying an additional 246 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in Apogee Therapeutics by 61.7% in the first quarter. EverSource Wealth Advisors LLC now owns 645 shares of the company’s stock worth $54,000 after buying an additional 246 shares during the period. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Rothschild & Co Redburn assumed coverage on Apogee Therapeutics in a research note on Friday, May 1st. They issued a “buy” rating and a $140.00 target price on the stock. Royal Bank Of Canada reduced their target price on Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating on the stock in a research note on Monday, March 2nd. Truist Financial reduced their target price on Apogee Therapeutics from $83.00 to $81.00 and set a “hold” rating on the stock in a research note on Wednesday, May 27th. Wedbush increased their target price on Apogee Therapeutics from $120.00 to $135.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Finally, Citigroup increased their target price on Apogee Therapeutics from $95.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Apogee Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $113.63.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor ROR?t, a master regulator of T cell-driven inflammatory pathways. By modulating ROR?t activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral ROR?t inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.